Bisphosphonate-associated osteonecrosis of the jaw: successful treatment at 2-year follow-up.
Aarabi
Shahram
S
Stanford, Calif.; and New York, N.Y. From the Department of Surgery, Stanford University School of Medicine, and the Department of Surgery, New York University School of Medicine.
Draper
Lawrence
L
Grayson
Barry
B
Gurtner
Geoffrey C
GC
D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use / Q000633:toxicity*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000556:secondary*; D003646:Debridement; D004164:Diphosphonates / Q000627:therapeutic use / Q000633:toxicity*; D005260:Female; D005500:Follow-Up Studies; D005598:Fractures, Spontaneous / Q000139:chemically induced / Q000601:surgery; D006801:Humans; D008334:Mandible / Q000601:surgery; D008336:Mandibular Diseases / Q000139:chemically induced* / Q000601:surgery*; D008337:Mandibular Fractures / Q000139:chemically induced / Q000601:surgery; D008866:Microsurgery; D008875:Middle Aged; D017090:Occlusal Splints; D009967:Orthodontic Appliances; D010020:Osteonecrosis / Q000139:chemically induced* / Q000601:surgery*; D000077268:Pamidronate; D013524:Surgical Flaps / Q000098:blood supply
D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate